Standard

Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. / Wu, Linghe; Baylan, Umit; van der Leeden, Britt et al.

In: International journal of cardiology, Vol. 349, 15.02.2022, p. 157-165.

Research output: Contribution to journal › Article › Academic › peer-review

Harvard

Wu, L, Baylan, U, van der Leeden, B, Schurink, B, Roos, E, Schalkwijk, CG, Bugiani, M, van der Valk, P, van Rossum, AC, Zeerleder, SS, Heunks, LMA, Boon, RA, de Boer, OJ, van der Wal, AC, Niessen, HWM & Krijnen, PAJ 2022, 'Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients', International journal of cardiology, vol. 349, pp. 157-165. https://doi.org/10.1016/j.ijcard.2021.11.079

APA

Wu, L., Baylan, U., van der Leeden, B., Schurink, B., Roos, E., Schalkwijk, C. G., Bugiani, M., van der Valk, P., van Rossum, A. C., Zeerleder, S. S., Heunks, L. M. A., Boon, R. A., de Boer, O. J., van der Wal, A. C., Niessen, H. W. M., & Krijnen, P. A. J. (2022). Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. International journal of cardiology, 349, 157-165. https://doi.org/10.1016/j.ijcard.2021.11.079

Vancouver

Wu L, Baylan U, van der Leeden B, Schurink B, Roos E, Schalkwijk CG et al. Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. International journal of cardiology. 2022 Feb 15;349:157-165. Epub 2021. doi: 10.1016/j.ijcard.2021.11.079

Author

Wu, Linghe ; Baylan, Umit ; van der Leeden, Britt et al. / Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. In: International journal of cardiology. 2022 ; Vol. 349. pp. 157-165.

BibTeX

@article{308bfb48d572495798caab3341ebbb21,
title = "Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients",
abstract = "Background: Compelling evidence has shown cardiac involvement in COVID-19 patients. However, the overall majority of these studies use data obtained during the first wave of the pandemic, while recently differences have been reported in disease course and mortality between first- and second wave COVID-19 patients. The aim of this study was to analyze and compare cardiac pathology between first- and second wave COVID-19 patients. Methods: Autopsied hearts from first- (n = 15) and second wave (n = 10) COVID-19 patients and from 18 non-COVID-19 control patients were (immuno)histochemically analyzed. CD45+ leukocyte, CD68+ macrophage and CD3+ T lymphocyte infiltration, cardiomyocyte necrosis and microvascular thrombosis were quantified. In addition, the procoagulant factors Tissue Factor (TF), Factor VII (FVII), Factor XII (FXII), the anticoagulant protein Dipeptidyl Peptidase 4 (DPP4) and the advanced glycation end-product N(ε)-Carboxymethyllysine (CML), as markers of microvascular thrombogenicity and dysfunction, were quantified. Results: Cardiac inflammation was significantly decreased in second wave compared to first wave COVID-19 patients, predominantly related to a decrease in infiltrated lymphocytes and the occurrence of lymphocytic myocarditis. This was accompanied by significant decreases in cardiomyocyte injury and microvascular thrombosis. Moreover, microvascular deposits of FVII and CML were significantly lower in second wave compared to first wave COVID-19 patients. Conclusions: These results show that in our cohort of fatal COVID-19 cases cardiac inflammation, cardiomyocyte injury and microvascular thrombogenicity were markedly decreased in second wave compared to first wave patients. This may reflect advances in COVID-19 treatment related to an increased use of steroids in the second COVID-19 wave.",
keywords = "COVID-19, First and second wave, Heart, Inflammation, Thrombosis microvasculature",
author = "Linghe Wu and Umit Baylan and {van der Leeden}, Britt and Bernadette Schurink and Eva Roos and Schalkwijk, {Casper G.} and Marianna Bugiani and {van der Valk}, Paul and {van Rossum}, {Albert C.} and Zeerleder, {Sacha S.} and Heunks, {Leo M. A.} and Boon, {Reinier A.} and {de Boer}, {Onno J.} and {van der Wal}, {Allard C.} and Niessen, {Hans W. M.} and Krijnen, {Paul A. J.}",
note = "Funding Information: This work was supported by the China Scholarship Council (Beijing, China, grant number 201708260020 to LW); Heath Holland (The Hague, The Netherlands, Sector Life Sciences & Health (LSH) - Topconsortia for Knowledge and Innovation (TKI) grant, number LSHM19106 to BvdL). Publisher Copyright: {\textcopyright} 2021 The Author(s)",
year = "2022",
month = feb,
day = "15",
doi = "10.1016/j.ijcard.2021.11.079",
language = "English",
volume = "349",
pages = "157--165",
journal = "International journal of cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients

AU - Wu, Linghe

AU - Baylan, Umit

AU - van der Leeden, Britt

AU - Schurink, Bernadette

AU - Roos, Eva

AU - Schalkwijk, Casper G.

AU - Bugiani, Marianna

AU - van der Valk, Paul

AU - van Rossum, Albert C.

AU - Zeerleder, Sacha S.

AU - Heunks, Leo M. A.

AU - Boon, Reinier A.

AU - de Boer, Onno J.

AU - van der Wal, Allard C.

AU - Niessen, Hans W. M.

AU - Krijnen, Paul A. J.

N1 - Funding Information: This work was supported by the China Scholarship Council (Beijing, China, grant number 201708260020 to LW); Heath Holland (The Hague, The Netherlands, Sector Life Sciences & Health (LSH) - Topconsortia for Knowledge and Innovation (TKI) grant, number LSHM19106 to BvdL). Publisher Copyright: © 2021 The Author(s)

PY - 2022/2/15

Y1 - 2022/2/15

N2 - Background: Compelling evidence has shown cardiac involvement in COVID-19 patients. However, the overall majority of these studies use data obtained during the first wave of the pandemic, while recently differences have been reported in disease course and mortality between first- and second wave COVID-19 patients. The aim of this study was to analyze and compare cardiac pathology between first- and second wave COVID-19 patients. Methods: Autopsied hearts from first- (n = 15) and second wave (n = 10) COVID-19 patients and from 18 non-COVID-19 control patients were (immuno)histochemically analyzed. CD45+ leukocyte, CD68+ macrophage and CD3+ T lymphocyte infiltration, cardiomyocyte necrosis and microvascular thrombosis were quantified. In addition, the procoagulant factors Tissue Factor (TF), Factor VII (FVII), Factor XII (FXII), the anticoagulant protein Dipeptidyl Peptidase 4 (DPP4) and the advanced glycation end-product N(ε)-Carboxymethyllysine (CML), as markers of microvascular thrombogenicity and dysfunction, were quantified. Results: Cardiac inflammation was significantly decreased in second wave compared to first wave COVID-19 patients, predominantly related to a decrease in infiltrated lymphocytes and the occurrence of lymphocytic myocarditis. This was accompanied by significant decreases in cardiomyocyte injury and microvascular thrombosis. Moreover, microvascular deposits of FVII and CML were significantly lower in second wave compared to first wave COVID-19 patients. Conclusions: These results show that in our cohort of fatal COVID-19 cases cardiac inflammation, cardiomyocyte injury and microvascular thrombogenicity were markedly decreased in second wave compared to first wave patients. This may reflect advances in COVID-19 treatment related to an increased use of steroids in the second COVID-19 wave.

AB - Background: Compelling evidence has shown cardiac involvement in COVID-19 patients. However, the overall majority of these studies use data obtained during the first wave of the pandemic, while recently differences have been reported in disease course and mortality between first- and second wave COVID-19 patients. The aim of this study was to analyze and compare cardiac pathology between first- and second wave COVID-19 patients. Methods: Autopsied hearts from first- (n = 15) and second wave (n = 10) COVID-19 patients and from 18 non-COVID-19 control patients were (immuno)histochemically analyzed. CD45+ leukocyte, CD68+ macrophage and CD3+ T lymphocyte infiltration, cardiomyocyte necrosis and microvascular thrombosis were quantified. In addition, the procoagulant factors Tissue Factor (TF), Factor VII (FVII), Factor XII (FXII), the anticoagulant protein Dipeptidyl Peptidase 4 (DPP4) and the advanced glycation end-product N(ε)-Carboxymethyllysine (CML), as markers of microvascular thrombogenicity and dysfunction, were quantified. Results: Cardiac inflammation was significantly decreased in second wave compared to first wave COVID-19 patients, predominantly related to a decrease in infiltrated lymphocytes and the occurrence of lymphocytic myocarditis. This was accompanied by significant decreases in cardiomyocyte injury and microvascular thrombosis. Moreover, microvascular deposits of FVII and CML were significantly lower in second wave compared to first wave COVID-19 patients. Conclusions: These results show that in our cohort of fatal COVID-19 cases cardiac inflammation, cardiomyocyte injury and microvascular thrombogenicity were markedly decreased in second wave compared to first wave patients. This may reflect advances in COVID-19 treatment related to an increased use of steroids in the second COVID-19 wave.

KW - COVID-19

KW - First and second wave

KW - Heart

KW - Inflammation

KW - Thrombosis microvasculature

UR - http://www.scopus.com/inward/record.url?scp=85120956677&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2021.11.079

DO - 10.1016/j.ijcard.2021.11.079

M3 - Article

C2 - 34871622

VL - 349

SP - 157

EP - 165

JO - International journal of cardiology

JF - International journal of cardiology

SN - 0167-5273

ER -

ID: 20800743